请选择 进入手机版 | 继续访问电脑版

搜索

Hepatitis C Elimination Public Welfare Project Started in Hengyang, Hunan

2021-4-20 19:44/ 发布者: admin/ 查看: 730/ 评论: 0


  China Hepatitis C Elimination Alliance Public Welfare Project Started in Hengyang on April 20. More than 80 healthcare workers including leaders of county CDCs in Hengyang, professionals of hepatitis C prevention and control, hospital leaders, infectious department directors and liver disease department directors participated in the training session. Five municipal medical institutions including Hengyang CDC, The First and Second Affiliated Hospital and Affiliated Nanhua Hospital of University of South China, Hengyang Central Hospital and Hengyang Third People’s Hospital were conferred the plaques of “prevention and control base” “diagnosis and treatment base” of China Hepatitis C Elimination Alliance Public Welfare Project. The project aims to cooperate to eliminate hepatitis C through cooperation of medical institutions in Hengyang.

  Under the guidance of Disease Control Division of Hunan Health Commission,the work of hepatitis C elimination in Hengyang was jointly organized and implemented by China Liver Health together with Hunan CDC, Hunan AIDS/STD Association,Hengyang Health Commission and Hengyang CDC. Academician Zhuang Hui, honorary chairman of China Liver Health, Li Jian, director of the National Center for AIDS/STD Control and Prevention of China CDC, Shen Yingsheng, deputy director of China Liver Health, Xie Ying, deputy director of Disease Control Division of Hunan Health Commission, director He Jianmei and deputy director Zheng Jun from the Center for AIDS/STD Control and Prevention of Hunan CDC, Zou Jianjun, director of Hengyang Health Commission,Li Zhiyong, chief of the disease control and prevention section of Hengyang Health Commission, Peng Weixiong, director of Hengyang CDC, Ren Qiong,chief of the Center for AIDS/STD Control and Prevention of Hengyang CDC and other leaders and experts from related hospitals attended the meeting. Chen Xi, deputy director of Hunan CDC presided over the project startup and training meeting. Gilead Sciences provided public welfare support.

Medical institutions of Hengyang cooperated to deal with the silent killer-hepatitis C

  Launched in the Great Hall of the People in Beijing in 2017, China Hepatitis C Elimination Alliance Public Welfare Project is committed to carrying out a series of public welfare activities under the guidance of the Ministry of Civil Affairs, Bureau of Disease Prevention and Control of National Health Commission,China CDC and WHO. 

  Xie Ying, deputy director of Disease Control Division of Hunan Health Commission delivered a speech and pointed that eliminating hepatitis C was one of the major tasks in implementing Healthy China 2030 plan. By integrating social resources, the implementation of China Hepatitis C Elimination Alliance Public Welfare Project in Hengyang, Hunan province was an effective attempt for infectious disease prevention and control. She hoped that the local CDCs, hospitals and health centers cooperate actively to promote hepatitis C screening, detection and prevention, and achieve eliminating hepatitis C in Hengyang as soon as possible.

  Zhuang Hui, academician of Chinese Academy of Engineering,honorary chairman of China Liver Health,general counsel of China Hepatitis C Elimination Alliance Public Welfare Project interpreted the burden of hepatitis C disease. Li Jian, director of the National Center for AIDS/STD Control and Prevention of China CDC interpreted the current situation of the hepatitis C epidemic in China.

  Viral hepatitis C is a class B infectious disease stipulated in the Law of China on the Prevention and Control of Infectious Diseases. Hepatitis C virus(HCV) is transmitted by blood and sexuality. In China, there are 10 million people infected with HCV. 70% of them have not been detected and effectively treated, which is a potential threat to their families and the society. Hepatitis C, known as a silent killer because of the insidious onset, can progress to severe diseases such as cirrhosis, and liver cancer. Hepatitis C can be completely cured with oral direct-acting antivirals (DAAs). These drugs have been included in the medical insurance of China. Drug prices have fallen by 85% since 2019, and treatment expenses have been greatly reduced.

    Shen Yingsheng, deputy director of China Liver Health introduced that, in order to improve the screening rate, detection rate and treatment rate of hepatitis C in Hengyang, relying on one prevention and control base and 5 diagnosis and treatment bases, China Hepatitis C Elimination Alliance Public Welfare Project in Hengyang will focus on two aspects.The first is to actively implement community publicity and training of primary-level doctors and nurses, and improve the acquaintance of people at high risk of hepatitis C infection, hepatitis C infected people, and primary-level doctors and nurses on the harm of hepatitis C, detection and treatment means, and medical insurance reimbursement policies. The second is to promote the screening management process of hepatitis C combined with the daily medical work of base hospitals, and promote the combination of the management department, clinical department, laboratory department and infection control department in medical institutions, strengthen the consultation and referral of infected hepatitis C persons, and promote the diagnosis and treatment of hepatitis C patients.

  At the training session, prof. Gong Guozhong from the Second Xiangya Hospital of Central South University interpreted the Management Process of Hepatitis C Hospital Screening of China(trial draft). Prof. Zhu Lihui from the Second Affiliated Hospital of University of South China delivered a speech on the advantages of whole-gene DAA drugs for hepatitis C treatment. Prof. Zhong Zhefeng from the Affiliated Nanhua Hospital of University of South China explained how to promote the elimination of hepatitis C through referral in hospitals. Prof. Peng Zhongtian from the First Affiliated Hospital of University of South China, presided over the academic exchange.


  Entrusted by China Liver Health,  Chen Xi, deputy director of Hunan CDC announced to award Hengyang CDC the title of prevention and treatment base of China Hepatitis C Elimination Alliance Public Welfare Project, award The First and Second Affiliated Hospital and Affiliated Nanhua Hospital of University of South China,Hengyang Central Hospital and Hengyang Third People’s Hospital the title of diagnosis and treatment base of China Hepatitis C Elimination Alliance Public Welfare Project, and to grant related experts as members of the National Expert Committee for Liver Health Promotion.

Xie Ying, deputy director of Disease Control Division of Hunan Health Commission, Chen Xi, deputy director of Hunan CDC, Zou Jianjun, director of Hengyang Health Commission, Peng Weixiong, director of Hengyang CDC,He Jianmei, director of the Center for AIDS/STD Control and Prevention of  Hunan CDC,Li Zhiyong,director of Disease Control Division of Hengyang Health Commission conferred plaques and certificates to relevant   institutions and experts.

The China Hepatitis C Elimination Alliance Public Welfare Project is sponsored by China Liver Health and co-organized by the Research Center of Infectious Diseases of Peking University, Chinese Foundation for Hepatitis Prevention and Control,Peking University Hepatology Institute, Chinese Society of Hepatology of Chinese Medical Association, Chinese Society of Infectious Diseases of Chinese Medical Association, Hepatology Institute of Jilin Province, Virtual Community of Hepatitis C, and Health Times of People’s Daily. Prof. Wei Lai, chairman of China Liver Health, served as the chief expert. Since the launch of the project, it has established cooperation with more than 140 medical and disease control institutions across the country, trained more than 4,000 medical workers onsite, and more than 100,000 online, and carried out more than 80,000 free screening cases.



相关分类

返回顶部